Search results for "E-F"

showing 10 items of 836 documents

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

From laparoscopic assisted radical vaginal hysterectomy to vaginal assisted laparoscopic radical hysterectomy

2011

Radical hysterectomy with pelvic lymphadenectomy is the standard surgical treatment for patients with early stage cervical cancer. The majority of radical hysterectomies are performed with the open technique. However, laparoscopic, combined laparoscopic and vaginal, and robotic-assisted approaches may also be used. Compared with the abdominal radical hysterectomy (ARH), laparoscopic techniques are associated with less blood loss, shorter hospital stay, better cosmesis, and faster recovery. A further breakthrough in laparoscopic technique can only be made if safety and oncological clearance are comparable with ARH. We describe the technique and results of laparoscopic assisted radical vagina…

AdultTime FactorsBlood Loss SurgicalUterine Cervical Neoplasmsurologic complicationDisease-Free Survivalvaginal assisted laparoscopic radical hysterectomyEarly cervical cancer; vaginal assisted laparoscopic radical hysterectomy; urologic complicationsYoung AdultEarly cervical cancerHysterectomy VaginalHumansIntraoperative ComplicationsAgedAged 80 and overObstetrics and Gynecologylaparoscopic assisted radical vaginal hysterectomyLength of StayMiddle AgedChemotherapy AdjuvantLymphatic MetastasisFemaleLaparoscopyRadiotherapy Adjuvanturologic complicationsLearning Curve
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Hemangiopericytoma of the Oral Cavity After a Ten-Year Follow-up

2007

Hemangiopericytoma (HPC) is a mesenchymal tumour that may be benign, malignant, or occur in an intermediate form. We report an unusual case of hemangiopericytoma located in the buccal mucosal region. The histopathologic features showed increased cellularity, necrosis, hemorrhage, low proliferation index, and 4 or less mitotic figures per 10 high-power fields. Since this histological pattern suggests an intermediate form characterized by unpredictable clinical behavior, life-long follow-up is essential. In this patient no recurrences or distant metastases were evident at 10-yr follow-up.

AdultTreatment Outcometumor of oral cavityMouth MucosaHumansFemaleMouth NeoplasmshemangiopericytomaDisease-Free SurvivalFollow-Up Studies
researchProduct

Disparities in nutritional adequacy of diets between different socioeconomic groups of Finnish adults

2022

Information on dietary adequacy is needed to assess food and nutrition security in a modern society, especially in the transition towards climate-friendly food systems. In this study, differences in the nutritional adequacy of diets among Finnish adults were evaluated in population groups of different education, income and urbanisation levels. The study used data from the FinDiet 2017 Survey (n = 1655, 18–74 years). Modelled usual intakes of foods and nutrients were evaluated relative to food-based dietary guidelines issued by the National Nutrition Council of Finland (FNNC) and with respect to nutrient adequacy following the Nordic Nutrition Recommendations and FNNC. For about half of the …

Adultkestävä kulutustulotusual intake modellingmacronutrientsruokavaliotravinteetravitsemussuosituksetsosioekonominen asemaEatingSuomiHumansravintoaineetFinlandsosioekonomiset tekijätdietary guidelinesNutrition and Dieteticsruokajärjestelmätsocioeconomic differencesurbanisationturvallisuusNutritional Requirementsruokavaliodietary recommendationsdietary intake; socioeconomic differences; urbanisation; 24 h dietary recall; usual intake modelling; dietary guidelines; dietary recommendations; macronutrients; micronutrients; climate-friendlyNutrition Surveysclimate-friendlyterveellisyysDietSocioeconomic FactorskoulutusmicronutrientseriarvoisuusFemalekaupungistuminendietary intakeravitsemus24 h dietary recallFood Science
researchProduct

Successful treatment of a young patient with locally advanced clear cell adenocarcinoma of the uterine cervix undergoing chemoradiation followed by r…

2014

Clear cell adenocarcinoma (CCAC) of the uterine cervix is a rare variant of cervical adenocarcinoma accounting for approximately 4-9% of this disease. Given the rarity of this pathological entity, the optimal treatment management is far from being defined. Earlier evidence suggested that the prognosis of patients bearing cervical CCAC is worse than with other histotypes, thus making the investigation of multimodal treatment strategies clinically worthwhile. Herein, we report the first case of locally advanced, large size cervical CCAC in a young woman who was triaged to concomitant chemoradiotherapy followed by radical surgery and experienced a pathologically assessed optimal response to th…

Adultmedicine.medical_specialtyAdvanced clear cell adenocarcinomaUterine Cervical NeoplasmRadical surgeryUterine Cervical NeoplasmsDisease-Free SurvivalObstetrics and gynaecologyadenocarcinoma uterine cervixUterine cervixmedicineHumansCombined Modality TherapyClear-cell adenocarcinomaRadical surgeryPathologicalSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryObstetrics and GynecologyMultimodal therapyChemoradiotherapy Adjuvantmedicine.diseaseMultimodal approachCombined Modality TherapyImmunohistochemistryMagnetic Resonance ImagingSurgeryChemoradiationReproductive MedicineAdenocarcinomaFemalebusinessChemoradiotherapyAdenocarcinoma Clear CellHuman
researchProduct

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovaria…

2013

Summary Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7. Methods ICON7 is a randomised, multicentre, open-label phase 3 trial. Between Dec 18, 2006, and Feb 16, 2009, after a surgical procedure aiming to debulk the disease, women with Inter…

Adultmedicine.medical_specialtyBevacizumabDrug-Related Side Effects and Adverse ReactionsAntibodies Monoclonal HumanizedDisease-Free Survivallaw.inventionchemistry.chemical_compoundRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingOvarian NeoplasmsIntention-to-treat analysisbusiness.industryStandard treatmentArticlesMiddle Agedmedicine.diseaseCarboplatinSurgeryBevacizumabClinical trialTreatment OutcomeOncologychemistryQuality of LifeFemaleOvarian cancerbusinessmedicine.drugThe Lancet Oncology
researchProduct

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

2007

ABSTRACT Background A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration …

Adultmedicine.medical_specialtyOrganoplatinum CompoundsAnemiaSettore MED/06 - Oncologia MedicaOvarian cancer recurrencedocetaxel ovarian cancer recurrence oxaliplatinPhases of clinical researchDocetaxelGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedOvarian NeoplasmsLeukopeniabusiness.industryHematologyMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenTreatment OutcomeOncologyDocetaxelDocetaxel; Ovarian cancer recurrence; OxaliplatinToxicityFemaleTaxoidsmedicine.symptomNeoplasm Recurrence LocalOvarian cancerbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Tumor Vascularity—A Novel Prognostic Factor in Advanced Cervical Carcinoma

1995

Objective: In the search for the optimal treatment of advanced cervical cancer, the identification of valid prognostic factors obtainable without histopathologic investigation of the entire tumor and the locoregional lymph nodes is of paramount interest. Tumor microvessel density has recently been demonstrated to correlate strongly with disease aggressiveness in breast cancer and other malignancies. Methods: We established a computerized image analysis system to quantify tumor microvascularity by using the closest-individual method, which determines the distribution of distances from random points within the tumor to the closest microvessel (DTCMV). Tumor microvascularity was assessed in pa…

Adultmedicine.medical_specialtyPathologyUterine Cervical NeoplasmsAdenocarcinomaDisease-Free SurvivalCarcinoma AdenosquamousBreast cancermedicineCarcinomaHumansProspective StudiesStage (cooking)Lymph nodeAgedNeoplasm StagingAged 80 and overCervical cancerEpitheliomabusiness.industryObstetrics and GynecologyMiddle AgedPrognosismedicine.diseasemedicine.anatomical_structureLymphatic systemOncologyCarcinoma Squamous CellRegression AnalysisFemaleHistopathologybusinessFollow-Up StudiesGynecologic Oncology
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct